Asthma and sinonasal diseases, particularly chronic rhinosinusitis with nasal polyps (CRSwNP), frequently coexist as part of the United Airway Disease (UAD), reflecting shared inflammatory pathways and physiopathologic mechanisms. They both significantly contribute as additional comorbidities to patient burden of symptoms and disease severity, and may guide the treatment approach, particularly when presenting together. The aim of this review was to explore the clinical interplay between asthma and sinonasal diseases, emphasizing epidemiologic links, shared immunologic pathways, and emerging management strategies, namely biologic therapies targeting type 2 (T2) inflammation. This approach enables integrated diagnostic and therapeutic approaches by targeting specific inflammatory mediators in a precision-medicine perspective. This may lead to a higher chance of achieving better outcomes in both upper and lower airways. Future studies should refine the treatment selection and evaluate long-term effects of biologic therapy across the upper and lower airways.
Ultrasound-Guided Needle Aspiration Biopsy for Superficial Cervical Lymphadenopathy: Diagnostic Yield Beyond Tuberculosis / Cefaloni, F., Schiavi, E., Morviducci, M., De Corso, E., Brunori, M., Masieri, S., Bonini, M.. - In: DIAGNOSTICS. - ISSN 2075-4418. - 14:5(2026). [10.3390/medsci14050568]
Ultrasound-Guided Needle Aspiration Biopsy for Superficial Cervical Lymphadenopathy: Diagnostic Yield Beyond Tuberculosis
Francesca Cefaloni;Enrico Schiavi;Matteo Morviducci
;Marco Brunori;Simonetta Masieri;Matteo Bonini
2026
Abstract
Asthma and sinonasal diseases, particularly chronic rhinosinusitis with nasal polyps (CRSwNP), frequently coexist as part of the United Airway Disease (UAD), reflecting shared inflammatory pathways and physiopathologic mechanisms. They both significantly contribute as additional comorbidities to patient burden of symptoms and disease severity, and may guide the treatment approach, particularly when presenting together. The aim of this review was to explore the clinical interplay between asthma and sinonasal diseases, emphasizing epidemiologic links, shared immunologic pathways, and emerging management strategies, namely biologic therapies targeting type 2 (T2) inflammation. This approach enables integrated diagnostic and therapeutic approaches by targeting specific inflammatory mediators in a precision-medicine perspective. This may lead to a higher chance of achieving better outcomes in both upper and lower airways. Future studies should refine the treatment selection and evaluate long-term effects of biologic therapy across the upper and lower airways.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cefaloni_Asthma_2026.pdf
accesso aperto
Note: Cefaloni_Asthma_2026
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
1.97 MB
Formato
Adobe PDF
|
1.97 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


